Cargando…
Canagliflozin-associated Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels
The Food and Drug Administration has approved the use of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for use in Type II diabetics. These are a relatively new addition to the armamentaria of diabetes management. Postmarketing surveillance is a witness to several side effects, a morbid one bei...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699011/ https://www.ncbi.nlm.nih.gov/pubmed/29279644 http://dx.doi.org/10.4103/ijccm.IJCCM_328_17 |